Serina Therapeutics is a clinical-stage biotech company focused on reformulating existing drugs using its proprietary POZ (poly(2-oxazoline)) polymer delivery platform. The core idea is to attach existing, well-understood drug molecules to the POZ polymer so they release slowly and continuously after a subcutaneous injection, avoiding the peaks and troughs of oral or standard injectable drugs. Serina's primary focus is Parkinson's disease, where erratic dopamine stimulation from standard oral therapies causes "OFF" periods and motor complications over time. Serina's lead candidate, SER-252, conjugates apomorphine to POZ for twice-weekly self-injection — designed to provide continuous dopaminergic stimulation without the skin reactions and daily infusion burden associated with the competing Onapgo product. SER-252 entered Phase 1b trials in early 2026. A second candidate, SER-214, conjugates rotigotine to POZ for weekly injection and completed Phase 1a; Serina plans to out-license this program. Beyond Parkinson's, Serina is developing POZ-lipids as an alternative to PEG-lipids in lipid nanoparticle drug delivery — the mechanism used in mRNA vaccines — targeting a growing concern about anti-PEG antibodies. Serina has already licensed this technology to Pfizer in a deal that included a $3M upfront payment plus milestones and royalties. Serina's business model combines internal drug development of SER-252 with broad platform licensing of POZ technology across RNA therapeutics, antibody-drug conjugates, and other applications it won't develop internally.